NCT07031596: Probiotic

Study on the Weight Loss Effects and Mechanisms of Probiotic Preparation Intervention in Weight Cyclers: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Not yet recruiting NA Last updated 12 June 2025

What this trial tests

NA trial testing WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100). in Obesity and Obesity-related Medical Conditions in 198 participants. Not yet recruiting.

Timeline

1 June 2025

Primary endpoint
1 December 2026

1 December 2026

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	198
Start date	1 June 2025
Primary completion	1 December 2026
Estimated completion	1 December 2026
Sites	1 location across China

Drugs / interventions tested

• WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100).
• WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.
• Placebo

Conditions studied

• Obesity and Obesity-related Medical Conditions — all drugs for Obesity and Obesity-related Medical Conditions →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 60, any sex, with Obesity and Obesity-related Medical Conditions. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Percentage of Participants with >5% Body Weight Loss
  Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
  Proportion of participants achieving ≥5% reduction in body weight from baseline (D0) to end of intervention (D85).

Sponsor's own description

1. Study Background and Purpose Obesity is a complex chronic disease closely linked to comorbidities such as cardiovascular disease, hypertension, and diabetes. With lifestyle changes, obesity prevalence continues to rise. Current treatments focus on weight loss through dietary control and exercise, but weight regain is common due to metabolic adaptations (e.g., post-caloric restriction). Gut microbiota play a critical role in weight management, and probiotics may reduce weight regain by modulating appetite and metabolism. Studies suggest probiotics enhance satiety and reduce appetite. This study aims to evaluate the potential of probiotics in obesity management, specifically their impact on gut microbiota modulation and hormonal regulation to mitigate weight regain. Ethical approval has been obtained from the Peking Union Medical College Hospital Ethics Committee.
2. Study Design

This 198-participant, randomized, interventional trial will assign subjects to three groups (1:1:1 ratio):

Placebo group (maltodextrin-based placebo) Probiotic Group 1 Probiotic Group 2 Randomization will be conducted via sealed envelopes (no researcher/participant bias). All groups receive standardized nutritional counseling, caloric restriction plans, and body composition assessments. Probiotics (produced by Shenzhen BaoShiJian Biotechnology Co., Ltd., compliant with standard Q/BSJ 0023S-2024) will be administered orally (2 bottles twice daily) for 84 days .
3. Study Procedure Informed Consent : Required before participation. Screening Phase : Demographic history, medical records, concomitant medications, validated questionnaires, body composition analysis, and blood/urine/stool tests.

Intervention : Daily probiotic or placebo intake for 84 days. Follow-ups : Visits at Day 42 and Day 85 for adherence checks, anthropometric measurements, and repeat testing.
4. Study Completion Duration : 84 days. Post-Study : Placebo group receives 1-month free probiotic supply; others return to standard care. A 30-day post-study follow-up (phone/WeChat) will assess safety.

Withdrawal : Participants may exit anytime. Investigators may withdraw participants for safety reasons.
5. Potential Benefits Personalized nutrition counseling and body composition reports. Free clinical evaluations and health coaching. Contribution to novel weight management strategies for weight-cycling populations.
6. Risks and Discomforts Adverse Events : Gastrointestinal symptoms or discomfort. Immediate reporting required for medical management.

Inconveniences :

3 on-site visits (blood/urine/stool tests, anthropometry) with fasting blood draws (\~7-20 mL/session).

1 telehealth visit (25 min questionnaire). Daily diary cards. Compensation : 150 RMB travel reimbursement + study-provided scales. 7. Alternative Options

Participants may opt for:

Intermittent fasting. Pharmacotherapy (e.g., GLP-1 agonists). Standard dietary recommendations. 8. New Information Any significant findings during the trial will be communicated to participants, who may choose to continue or withdraw.

9\. Costs and Reimbursement No-cost : All investigational products (probiotics/placebo), lab tests, and body composition analyses.

Reimbursement : 150 RMB travel compensation + study tools (body fat scale, food scale, tape measure).

10\. Adverse Event Policy All injuries attributed to the intervention will be covered by Shenzhen BaoShiJian Biotechnology Co., Ltd. 's insurance. Legal liability extends beyond insurance coverage.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.